First published 9/30/2026, 8:03:15 AM · Last updated 9/30/2026, 8:03:15 AM

Analysis of 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) administration in MATTERHORN: A randomized, Phase 3 study of durvalumab (D) plus FLOT in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma

Journal article reporting an analysis related to the MATTERHORN randomized Phase 3 trial of durvalumab plus FLOT for resectable gastric / gastroesophageal junction adenocarcinoma. The provided source data include no study results, locations, or additional details beyond publication metadata.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 2/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 6/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

It documents a Phase 3 clinical trial regimen relevant to treatment of resectable gastric/GEJ adenocarcinoma.

Sources

Analysis of 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) administration in MATTERHORN: A randomized, Phase 3 study of durvalumab (D) plus FLOT in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma

Report an issue